Business News

The National Anti-Profiteering Authority (NAA) are questioning around 150 consumer goods and pharma companies regarding their stocks with the distributors and stockists on June 30,2017 were sold at low cost after the GST rollout. These were some of the questions the NAA investigators are looking for answers. The NAA issues a letter to top leading …

Finally, Indian pharma companies are finding a way to enter the world’s second largest pharmaceutical market which is attractive and profitable market of China. Usually it takes 5 years to get n approval but the Indian drug regulators get the approval for the drug product within 3-6 months. “They (the China Food and Drug Administration, …

On Tuesday’s trading session the pharma stocks were down during the last hour, the Biocon was down 1.52 percent, Sun Pharmaceutical industries (down 1.33 percent),Divi’s Laboratories ( down 0.95 percent ), Lupin ( down 0.41 percent ), whereas Aurobindo pharma and Cipla (down 0.38 percent ) were incurring losses, keeping the sectoral index unhappy. Around …

China which is the second largest drug market after US has agreed to provide a specific training programme for the domestic pharmaceutical industries to understand their regulatory system, this will promote the India’s exports, a senior government official said. . rnrn “China has assured us that they would provide a platform for Indian exports of …

As the Sun pharma’s Halol plant got clearance from the US FDA brought the pharma stocks into lime light on Wednesday giving a big relax to the pharma stocks. The Nifty pharma indexed closed at up to 0.9 percent at 8,948.95 and is up to 13 percent from recent lows, showing the improvement of the …

Sun Pharma’s Halol plant in Gujarat, India has finally got some relief from the US FDA after receiving satisfactory report from the Food and drug administration. Since 2014 the plant faces many issues with the manufacturing standards and the pressure was piled up after receiving a warning letter for this plant I Gujarat in 2015. …

The Organization of Pharmaceutical Producers of India-Oppi, which represents the research-based pharmaceutical companies in India and involved with the government and other stakeholders to get sustainable healthcare solutions called for adopting the global quality standard and brought all the stakeholders such as regulators, industry and governments to work together for the growth of the sector. …

Drug firm Lupin is now focusing on generics, biosimilar and speciality medicines to be the growth driver for going forward as per the investor presentation by the company. Although the company is sustaining and growing its presence in the generic segment, the company is planning for investing heavily in developing high barrier products in complex …

During Friday trade the pharma stocks were the top gainer among the sectoral indices on NSE. The Nifty Pharma index was trading 3.02 per cent up at 8,502 around 12:25 pm. The pharma stocks were rallying amid a fresh fall in the Indian rupee against the US dollar. The Sun Pharmaceuticals were the top gainer …

Tuesday afternoon the pharma stocks were trading mixed. It was reported that the shares of Candila Healthcare (up 1.20 per cent), Glenmark Pharmaceuticals (up 0.93 per cent) and Aurobindo PharmaNSE 4.69 % (up 0.73 per cent) were trading with gains. Whereas Dr.Reddy’s Laboratories (up 0.50 per cent) ,Divi's Laboratories (up 0.50 per cent), and Cipla …

As per the top company officials the Hyderabad based organization Dr. Reddy in planning to launch 15 plus products in US in 2018-19. Usually they prepare them self for up to 10-15 launches, but as per the company's CFO Saumen Chakraborty told analysts in a call."Normally every year, based on our portfolio and R&D investments, …

Little over six months from the launching of their first biosimilar drug, Biocon-Mylan got another approval for their second biosimilar drug on Tuesday from US Food and Drug Administration.  The second biosimilar drug which is pegfilgrastim, is a drug used to increase the white blood count of cancer patient, Biocon and Mlyan said in a …